SMAD2
Chr 18ADSMAD family member 2
Also known as: CHTD8, JV18, JV18-1, LDS6, MADH2, MADR2, hMAD-2, hSMAD2
The SMAD2 protein is an intracellular signal transducer and transcriptional modulator that mediates TGF-beta and activin signaling pathways, regulating cellular processes including proliferation, apoptosis, and differentiation. Mutations cause autosomal dominant Loeys-Dietz syndrome 6 and congenital heart defects with or without heterotaxy, primarily affecting cardiovascular and connective tissue systems. The gene is highly constrained against loss-of-function variants (pLI 0.997, LOEUF 0.259), indicating that such mutations are likely to cause significant developmental effects.
Definitive — sufficient evidence for diagnostic panels
2 total gene-disease associations curated
Population Genetics & Constraint
gnomAD v4 — loss-of-function & missense intolerance
Highly LoF-intolerant (top ~10% of genes)
Highly missense-constrained (top ~0.1%)
The highest-scoring mechanism for this gene is loss-of-function (haploinsufficiency).
Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.
ClinVar Variant Classifications
99 submitted variants in ClinVar
Classification Summary
Curated Variants Distribution
Classified variants from ClinVar · 5 ACMG categories
| Classification | LoF | Missense + Inframe | Non-coding | Synonymous | Total |
|---|---|---|---|---|---|
Pathogenic | 3 | 0 | 1 | 0 | 4 |
Likely Pathogenic | 2 | 0 | 1 | 0 | 3 |
VUS | 0 | 39 | 6 | 0 | 45 |
Likely Benign | 0 | 0 | 11 | 16 | 27 |
Benign | 0 | 0 | 2 | 0 | 2 |
| Total | 5 | 39 | 21 | 16 | 81 |
LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly
View in ClinVar →Protein Context — Lollipop Plot
SMAD2 · protein map & ClinVar variants
Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.
3D Protein StructureAlphaFold
External Resources
Links to major genomics databases and tools
Clinical Trials
Active and recruiting trials from ClinicalTrials.gov
Characterizing Matrix Metalloproteinase-12 (MMP12) in Sputum
RECRUITINGThis Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling
NOT YET RECRUITINGExternal Resources
Links to major genomics databases and tools